Centre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
PLoS Pathog. 2018 Jun 21;14(6):e1007084. doi: 10.1371/journal.ppat.1007084. eCollection 2018 Jun.
With the antibiotic development pipeline running dry, many fear that we might soon run out of treatment options. High-density infections are particularly difficult to treat due to their adaptive multidrug-resistance and currently there are no therapies that adequately address this important issue. Here, a large-scale in vivo study was performed to enhance the activity of antibiotics to treat high-density infections caused by multidrug-resistant Gram-positive and Gram-negative bacteria. It was shown that synthetic peptides can be used in conjunction with the antibiotics ciprofloxacin, meropenem, erythromycin, gentamicin, and vancomycin to improve the treatment outcome of murine cutaneous abscesses caused by clinical hard-to-treat pathogens including all ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter cloacae) pathogens and Escherichia coli. Promisingly, combination treatment often showed synergistic effects that significantly reduced abscess sizes and/or improved clearance of bacterial isolates from the infection site, regardless of the antibiotic mode of action. In vitro data suggest that the mechanisms of peptide action in vivo include enhancement of antibiotic penetration and potential disruption of the stringent stress response.
随着抗生素研发管道枯竭,许多人担心我们可能很快就会耗尽治疗选择。高密度感染由于其适应性的多药耐药性而特别难以治疗,目前尚无充分解决这一重要问题的疗法。在这里,进行了一项大规模的体内研究,以增强抗生素的活性,以治疗由耐多药革兰氏阳性和革兰氏阴性细菌引起的高密度感染。结果表明,可以将合成肽与抗生素环丙沙星、美罗培南、红霉素、庆大霉素和万古霉素联合使用,以改善由临床难以治疗的病原体引起的小鼠皮肤脓肿的治疗效果,包括所有 ESKAPE(粪肠球菌、金黄色葡萄球菌、肺炎克雷伯菌、鲍曼不动杆菌、铜绿假单胞菌、阴沟肠杆菌)病原体和大肠杆菌。有希望的是,联合治疗通常表现出协同作用,可显著减小脓肿大小和/或提高从感染部位清除细菌分离物的能力,而与抗生素的作用模式无关。体外数据表明,肽在体内的作用机制包括增强抗生素的穿透性和潜在破坏严格应激反应。